Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients

Clinical Infectious Diseases

Volumn 48, Issue 6, 2009, Pages 745-755

  Sun, Hsin Yun ^a   Singh, Nina ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; APOPTOSIS INDUCING FACTOR; ATORVASTATIN; C REACTIVE PROTEIN; CASPOFUNGIN; CAVEOLIN 1; CERIVASTATIN; COMPACTIN; ERGOSTEROL; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA CONVERTING ENZYME; ITRACONAZOLE; LATENT MEMBRANE PROTEIN 1; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIGNAL PEPTIDE; SIMVASTATIN; VORICONAZOLE; CELL CYCLE PROTEIN; IMMUNOLOGIC FACTOR; STN PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIGEN EXPRESSION; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BACTEREMIA; BACTERIAL GROWTH; BK VIRUS; CANDIDA; CANDIDIASIS; CARCINOGENESIS; CAVEOLA; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CORONARY ARTERY OBSTRUCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DNA SYNTHESIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DYSLIPIDEMIA; EPSTEIN BARR VIRUS; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; GROWTH INHIBITION; HELPER CELL; HEMODIALYSIS; HEPATITIS C; HOSPITALIZATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION COMPLICATION; INFECTION RISK; INFLUENZA; INTERNALIZATION; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; LIPID RAFT; LYMPHOPROLIFERATIVE DISEASE; METABOLIC DISORDER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PENICILLIUM CHRYSOGENUM; PLEIOTROPY; PNEUMONIA; POLYOMA VIRUS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRENYLATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PRENYLATION; REVASCULARIZATION; RISK REDUCTION; SEPSIS; SPORANGIOSPORE; STAPHYLOCOCCAL BACTEREMIA; TH1 CELL; TREATMENT RESPONSE; TUBERCULOSIS; VIRULENCE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; ZYGOMYCETES; BACTERIUM; DRUG EFFECT; FUNGUS; REVIEW; TRANSPLANTATION; VIRUS;

ANTI-INFECTIVE AGENTS; BACTERIA; CELL CYCLE PROTEINS; FUNGI; HUMANS; IMMUNOLOGIC FACTORS; SEPSIS; TRANSPLANTATION; VIRUSES;

EID: 62449100121     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597039     Document Type: Article

References (154)

1. Freeman RB Jr, Stef'fick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8:958-76.
2. Leichtman AB, Cohen D, Keith D, et al. Kidney and pancreas transplantation in the United States, 1997-2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 2008;8:946-57.
3. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, Murray S. Heart and lung transplantation in the United States, 1997-2006. Am J Transplant 2008;8:977-87.
4. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report, 2008. J Heart Lung Transplant 2008;27:957-69.
5. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007;83:1141-50.
6. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004;23(Suppl 5):S187-93.
7. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004;23(Suppl 5):S194-201.
8. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001;181:475-9.
9. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-5.
10. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9.
11. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008;51(Suppl 1):S1-320.
12. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report, 2008. J Heart Lung Transplant 2008;27:943-56.
13. Gazi IF, Liberopoulos EN, Athyros VG, Elisaf M, Mikhailidis DP. Statins and solid organ transplantation. Curr Pharm Des 2006;12:4771-83.
14. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003;63:360-4.
15. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31.
16. Samman A, Imai C, Straatman L, Frolich J, Humphries K, Ignaszewski A. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transplant 2005;24:1008-13.
17. Prasad GV, Kim SJ, Huang M, et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl- coenzyme a reductase inhibitors (statins). Am J Transplant 2004;4:1897- 903.
18. Lubitz SA, Pinney S, Wisnivesky JP, Gass A, Baran DA. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant 2007;26:264-72.
19. Masterson R, Hewitson T, Leikis M, Walker R, Cohney S, Becker G. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005;80:332-8.
20. Nurhan Ozdemir F, Akcay A, Sezer S, et al. Effect of simvastatin in the treatment of highly sensitized dialysis patients: the pre and postrenal transplantation follow-up outcomes. Transpl Immunol 2004;13:39-42.
21. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002;40:638-43.
22. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004;36:1539-41.
23. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003;167:1271-8.
24. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbauer R. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 2008;19:2211-8.
25. Lisik W, Schoenberg L, Lasky RE, Kahan BD. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen. Transplant Proc 2007;39:3086-92.
26. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
27. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003;107:93-7.
28. Wenke K, Meiser B, Thiery J, Reichart B. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz 2005;30:431-2.
29. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
30. Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001;59:1473-9.
31. Asberg A, Hartmann A, Fjeldsa E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 2001;16:1920-4.
32. Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis 2003;41:1088-96.
33. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: posthoc subgroup analyses of the ALERT Study. Am J Transplant 2004;4:988-95.
34. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-36.
35. Seron D, Oppenheimer F, Pallardo LM, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation 2008;86:82-7.
36. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:1736-40.
37. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005;24:63-6.
38. Argent E, Kainer G, Aitken M, Rosenberg AR, Mackie FE. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 2003;7:38-42.
39. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004;23:317-22.
40. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007;13:3622-36.
41. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
42. Ravipati G, Aronow WS, Ahn C, Channamsetty V, Sekhri V. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins. Am J Cardiol 2006;98:1170-1.
43. McGirt MJ, Perler BA, Brooke BS, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005;42:829-36; discussion, 36-7.
44. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005;36:2072-6.
45. Brooke BS, McGirt MJ, Woodworth GF, et al. Preoperative statin and diuretic use influence the presentation of patients undergoing carotid endarterectomy: results of a large single-institution case-control study. J Vasc Surg 2007;45:298-303.
46. LaMuraglia GM, Stoner MC, Brewster DC, et al. Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. J Vasc Surg 2005;41:762-8.
47. Tamargo J, Caballero R, Gomez R, Nunez L, Vaquero M, Delpon E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007;114:107-26.
48. Bae JH, Bassenge E, Kim KY, Synn YC, Park KR, Schwemmer M. Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther 2004;9:185-92.
49. Messerli AW, Aronow HD, Sprecher DL. The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI. Cleve Clin J Med 2003; 70:561-6.
50. Iwata A, Miura S, Shirai K, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006;45:885-90.
51. Nishikawa H, Miura S, Shimomura H, et al. Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis. J Cardiol 2005;45:107-13.
52. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51.
53. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the Greek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27.
54. Tonelli M. The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol 2006;21:608-12.
55. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34.
56. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot Tokyo 1976;29:1346-8.
57. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
58. Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 1994;10:31-54.
59. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266- 71.
60. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
61. Rosenson RS. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur Heart J 2003;24:1993-4.
62. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004;110:1296-302.
63. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
64. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999;292:1-9.
65. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005;288:L1026-32.
66. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85.
67. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant 2002;17(Suppl 4):26-8.
68. Kasiske B, Cosio EG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13-53.
69. Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 2007;297:1455- 64.
70. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leutkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957-61.
71. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-8.
72. Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-8.
73. Martin CP, Talbert RL, Burgess DS, Peters JI. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 2007;27:20-6.
74. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-9.
75. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7.
76. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-6.
77. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005;6:82.
78. Schmidt H, Hennen R, Keller A, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006;32:1248-51.
79. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003;107:258-63.
80. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.
81. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007;27:325-32.
82. Hsu J, Andes DR, Knasinski V, Safdar N. Statins Are Associated with Improved Outcomes of Bloodstream Infection in Solid Organ Transplant Recipients [abstract K-1455]. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2008.
83. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-68.
84. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008;100:288-98.
85. Li X, Klintman D, Weitz-Schmidt G, Schramm R, Thorlacius H. Lymphocyte function antigen-1 mediates leukocyte adhesion and subsequent liver damage in endotoxemic mice. Br J Pharmacol 2004;141:709-16.
86. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61:362-4.
87. Pentikainen PJ, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;32:136-40.
88. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus α-toxin. Circulation 2002;106:2104-10.
89. Horn MP, Knecht SM, Rushing FL, et al. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 2008;326:135-43.
90. Kinjo Y, Kawakami K, Uezu K, et al. Contribution of IL-18 to Thl response and host defense against infection by Mycobacterium tuberculosis a comparative study with IL-12p40. J Immunol 2002;169:323-9.
91. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest 2000;80:759-67.
92. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
93. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 1997;386:619-23.
94. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. Nature 1992;356:768-74.
95. Montero MT, Hernandez O, Suarez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Thl-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000;153:303-13.
96. Parks LW, Casey wm. Physiological implications of sterol biosynthesis in yeast. Annu Rev Microbiol 1995;49:95-116.
97. Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol 2003;41:417-25.
98. Gyetvai A, Emri T, Takacs K, et al. Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 2006;6:1140-8.
99. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002;51:105-9.
100. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997;41:850-2.
101. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006;262:9-13.
102. Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res 2007;7:436-41.
103. Roze LV, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998;25:119-33.
104. O'Connor RM, McArthur CR, Clark-Walker GD. Respiratory-deficient mutants of Torulopsis glabrata, a yeast with circular mitochondrial deoxyribonucleic acid of 6 mu m. J Bacteriol 1976;126:959-68.
105. Prevention CfDCa. National Diabetes Surveillance System. Prevalence of diabetes. 6 October 2005. Available at: http://www.cdc.gov/diabetes/ statistics/prev/national. Accessed 31 August 2008.
106. RodenMM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
107. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006;50:96-103.
108. Galgoczy L, Papp T, Lukacs G, Leiter E, Pocsi I, Vagvolgyi C. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 2007;270:109-15.
109. Lukacs G, Papp T, Nyilasi I, Nagy E, Vagvolgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004;42:5400-2.
110. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007;44:1089-90.
111. Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W. Antifungal activity of statins against Aspergillus species. Med Mycol 2007;45:589-93.
112. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 2008;60:369-73.
113. Moriyama T, Marquez JP, Wakatsuki T, Sorokin A. Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. J Virol 2007;81:8552-62.
114. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480-6.
115. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-8.
116. Moriyama T, Sorokin A. Repression of BK virus infection of human renal proximal tubular epithelial cells by pravastatin. Transplantation 2008;85:1311-7.
117. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-27.
118. Fearon WF, Potena L, Hirohata A, et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 2007;83:700-5.
119. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003;75:839-43.
120. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
121. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
122. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant 2008;12:442-6.
123. Potena L, Frascaroli G, Grigioni F, et al. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004;109:532-6.
124. Speir E, Yu ZX, Ferrans VJ, Huang ES, Epstein SE. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998;83:210-6.
125. Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS Jr, Huang ES. Multiple mechanisms are implicated in the regulation of NF-κ B activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A 1993;90:1107-11.
126. Cohen JL Epstein-Barr virus infection. N Engl J Med 2000;343:481- 92.
127. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43(3 Pt 2):831-40.
128. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-82.
129. Wang R Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
130. Cohen JI. HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. Br J Cancer 2005;92:1593-8.
131. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κ B activation. Mol Cell Biol 1996 ;16:7098-108.
132. Higuchi M, Izumi KM, Kieff E. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci U S A 2001;98:4675-80.
133. Kaykas A, Worringer K, Sugden B. CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J 2001;20:2641-54.
134. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A 2004;101:4960-5.
135. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol 2003;77:4160-8.
136. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004;324:450-61.
137. Wang C, Gale M Jr, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18:425-34.
138. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003;100:15865-70.
139. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005;102:2561-6.
140. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006;44:117-25.
141. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145-50.
142. George JO, Kenedi C, Brown A, et al. A pilot study to assess the impact of rosuvastatin therapy on HCV RNA and lipid fractions in chronic hepatitis C patients [abstract A741]. Gastroenterology 2007;132(Suppl 2):445.
143. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007;45:895-8.
144. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:1383-9.
145. Singh V, Carey EJ, Rudraraju M, et al. Role of HMG-CoA reductase therapy in hepatitis C treatment outcomes [abstract A789|. Gastroenterology 2007;132(Suppl 2):1852.
146. Gilbert C, Bergeron M, Methot S, Giguere JF, Tremblay MJ. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 2005;18:474-89.
147. del Real G, Jimenez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004;200:541-7.
148. Probasco JC, Spudich SS, Critchfield J, et al. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology 2008;71:521-4.
149. Waters L, Stebbing J, Jones R, et al. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005;39:637-8.
150. Sklar PA, Masur H, Grubb JR, et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005;19:1109-11.
151. Letendre SL, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007;2:120-7.
152. Negredo E, Clotet B, Puig J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 2006;20:619-21.
153. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64.
154. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.